Pharming Group (PHAR) Projected to Announce Quarterly Earnings on Thursday

Pharming Group (NASDAQ:PHAR) is expected to announce its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Pharming Group to post earnings of $0.0630 per share and revenue of $101.2830 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 7:30 AM ET.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, May 7th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.12). Pharming Group had a net margin of 3.30% and a return on equity of 4.64%. The business had revenue of $72.45 million during the quarter, compared to analysts’ expectations of $92.06 million. On average, analysts expect Pharming Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Pharming Group Stock Down 2.6%

Pharming Group stock opened at $12.79 on Thursday. Pharming Group has a 1-year low of $9.54 and a 1-year high of $21.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06. The stock has a market cap of $905.28 million, a PE ratio of 79.94 and a beta of -0.04. The stock’s fifty day moving average is $13.13 and its two-hundred day moving average is $15.44.

Institutional Trading of Pharming Group

A number of hedge funds and other institutional investors have recently made changes to their positions in PHAR. EverSource Wealth Advisors LLC purchased a new stake in shares of Pharming Group in the 2nd quarter valued at about $32,000. SmartHarvest Portfolios LLC purchased a new position in Pharming Group during the 4th quarter worth approximately $224,000. Millennium Management LLC purchased a new position in Pharming Group during the 4th quarter worth approximately $360,000. Finally, NewEdge Advisors LLC increased its position in Pharming Group by 11,310.3% during the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock worth $510,000 after buying an additional 28,615 shares during the period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PHAR. Weiss Ratings cut Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Canaccord Genuity Group started coverage on Pharming Group in a research note on Friday, April 10th. They set a “buy” rating and a $37.00 target price for the company. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Finally, Wall Street Zen lowered shares of Pharming Group from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Pharming Group currently has an average rating of “Hold” and a consensus target price of $38.33.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.